海正生材8月28日获融资买入987.00万元，融资余额4171.59万元

Core Viewpoint - The financial performance of Zhejiang Haizheng Biological Materials Co., Ltd. shows a decline in revenue and net profit, indicating potential challenges in the company's operations and market conditions [2]. Financing Summary - On August 28, Haizheng Biological Materials experienced a financing buy-in of 9.87 million yuan, with a net buy of 3.39 million yuan after repayments [1]. - The total financing balance as of August 28 is 41.72 million yuan, accounting for 2.39% of the circulating market value, which is above the 90th percentile of the past year [1]. - The company had no short selling activity on August 28, with a short selling balance of 0.00 yuan, indicating a lack of bearish sentiment [1]. Shareholder and Financial Performance Summary - As of June 30, the number of shareholders increased by 11.75% to 7,457, while the average circulating shares per person decreased by 10.51% to 15,787 shares [2]. - For the first half of 2025, the company reported a revenue of 408 million yuan, a year-on-year decrease of 5.28%, and a net profit of 3.18 million yuan, down 87.32% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 42.49 million yuan in dividends [2]. - Among the top ten circulating shareholders, Guangfa Technology Innovation Mixed A (008638) is the fifth largest, holding 7.05 million shares as a new shareholder [2].